Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study


Summary

Background For young children with peanut allergy, dietary avoidance is the current standard of care. We aimed to assess whether peanut oral immunotherapy can induce desensitisation (an increased allergic reaction threshold while on therapy) or remission (a state of non-responsiveness after discontinuation of immunotherapy) in this population.

Methods We did a randomised, double-blind, placebo-controlled study in five US academic medical centres. Eligible participants were children aged 12 to younger than 48 months who were reactive to 500 mg or less of peanut protein during a double-blind, placebo-controlled food challenge (DBPCFC). Participants were randomly assigned by use of a computer, in a 2:1 allocation ratio, to receive peanut oral immunotherapy or placebo for 134 weeks (2000 mg peanut protein per day) followed by 26 weeks of avoidance, with participants and study staff and investigators masked to group assignment. The primary outcome was desensitisation at the end of treatment (week 134), and remission after avoidance (week 160), as the key secondary outcome, were assessed by DBPCFC to 5000 mg in the intention-to-treat population. Safety and immunological parameters were assessed in the same population. This trial is registered on ClinicalTrials.gov, NCT03345160.

Findings Between Aug 13, 2013, and Oct 1, 2015, 146 children, with a median age of 39·3 months (IQR 30·8–44·7), were randomly assigned to receive peanut oral immunotherapy (96 participants) or placebo (50 participants). At week 134, 68 (71%, 95% CI 61–80) of 96 participants who received peanut oral immunotherapy compared with one (2%), 0·05–11) of 50 who received placebo met the primary outcome of desensitisation (risk difference [RD] 69%, 95% CI 59–79; p<0·0001). The median cumulative tolerated dose during the week 134 DBPCFC was 5005 mg (IQR 3755–5005) for peanut oral immunotherapy versus 5 mg (0–105) for placebo (p<0·0001). All avoidance, 20 (21%, 95% CI 13–30) of 96 participants receiving peanut oral immunotherapy compared with one (2%), 0·05–11) of 50 receiving placebo met remission criteria (RD 19%, 95% CI 10–28; p=0·0021). The median cumulative tolerated dose during the week 160 DBPCFC was 775 mg (IQR 0–2755) for peanut oral immunotherapy and 0 mg (0–55) for placebo (p<0·0001). A significant proportion of participants receiving peanut oral immunotherapy who passed the 5000 mg DBPCFC at week 134 could no longer tolerate 5000 mg at week 160 (p<0·001). The participant receiving placebo who was desensitised at week 134 also achieved remission at week 160. Compared with placebo, peanut oral immunotherapy decreased peanut-specific and Ara h2-specific IgE, skin prick test, and basophil activation, and increased peanut-specific and Ara h2-specific IgG4 at weeks 134 and 160. By use of multivariable regression analysis of participants receiving peanut oral immunotherapy, younger age and lower baseline peanut-specific IgE was predictive of remission. Most participants (98% with peanut oral immunotherapy vs 80% with placebo) had at least one oral immunotherapy dosing reaction, predominantly mild to moderate and occurring more frequently in participants receiving peanut oral immunotherapy. 35 oral immunotherapy dosing events with moderate symptoms were treated with epinephrine in 21 participants receiving peanut oral immunotherapy.

Interpretation In children with a peanut allergy, initiation of peanut oral immunotherapy before age 4 years was associated with an increase in both desensitisation and remission. Development of remission correlated with immunological biomarkers. The outcomes suggest a window of opportunity at a young age for intervention to induce remission of peanut allergy.

Funding National Institute of Allergy and Infectious Diseases, Immune Tolerance Network.

Copyright © 2022 Elsevier Ltd. All rights reserved.
Introduction

Peanut allergy remains an important health and economic concern, affecting about 2% of the US paediatric population.1,2 Most children with peanut allergy remain allergic for their lifetime,3,4 and the risk of peanut-induced anaphylaxis from accidental exposure is substantial.5 Existing preventive strategies focus on early dietary peanut introduction to reduce the risk of developing peanut allergy.6,7 For individuals who are peanut allergic, dietary restriction of peanut remains the mainstay for management. Despite efforts to use strict allergen avoidance, one study reported that the patient-reported, annualised allergic reaction rate among preschool children (aged 3–15 months) who have a food allergy was 0.81 (95% CI 0.76–0.85) per year,8 highlighting the need for safe and effective therapies.

To address these concerns, diverse immunotherapeutic strategies have been investigated in clinical trials. One oral immunotherapy product has recently received US Food and Drug Administration (FDA) approval.9 Peanut oral immunotherapy uses ingested peanut to modulate immune responses and raise the allergic reaction threshold. Trials in school-aged children and young adults have consistently shown the capacity of this therapy to induce desensitisation (defined as an increased allergic reaction threshold while on therapy) in the majority (50–70%) of participants treated, although few have tested a threshold as high as 5000 mg of peanut protein.10–13 Investigators have sought to define the durability of reduced clinical responsiveness, initially using the term sustained unresponsiveness to describe the absence of clinical reactivity after discontinuing therapy for short periods of time (typically 4–8 weeks). In the past few years, the term remission has been used to better describe this non-responsive state after completion of immunotherapy.14,15 Remission describes the concept of disease quiescence that might be of unknown duration compared with permanent immune tolerance, but the relationship of remission to tolerance has not been proven to date. Studies are difficult to compare due to the variations noted but, overall, they have shown a limited duration of a remission-like clinical response after peanut oral immunotherapy.16–18

Because oral immunotherapy is immunomodulatory,19 intervening early in life, while the immune system is maturing, might be more effective. The DEVIL Trial,19 as well as a real-world safety trial of peanut oral immunotherapy,20 showed positive clinical outcomes in children with peanut allergy by starting oral immunotherapy between the ages of 9 and 71 months, providing proof of concept that peanut oral immunotherapy might be administered safely at young ages with a potential for enhanced effectiveness. Therefore, we designed the first randomised, blinded, placebo-controlled, multicentre trial of peanut oral immunotherapy in children younger than 4 years done in a multicentre (five US academic centres) trial design. The study provides long-term clinical efficacy, safety, and novel immunological data, along with predictors of response, among young children. These findings could inform clinicians about the potential benefits and risks of peanut oral immunotherapy for these patients.

Implications of the available evidence

The IMPACT trial shows that peanut oral immunotherapy induces desensitisation in most young children treated, and, in a subset of these children, induces remission, especially in the youngest children with lower peanut-specific IgE at the beginning of treatment. Although most children, from both the peanut oral immunotherapy and placebo groups, had dosing reactions during oral immunotherapy, most were mild to moderate, with epinephrine given in 21 participants for 35 peanut oral immunotherapy dosing reactions over the 134-week daily dosing period. Benefits noted in the youngest participants suggest that there is a therapeutic window of opportunity for inducing remission such that intervention at a young age with peanut oral immunotherapy might improve treatment outcomes for patients with peanut allergy.

Research in context

Evidence before this study

We actively monitor relevant publications and do literature reviews on a regular basis to ensure the most relevant, evidence-based information was included in the study design and manuscript. Peanut oral immunotherapy has been studied predominantly in school-age children, except for two small, single-centre studies in preschool children. Findings from these trials have shown that peanut oral immunotherapy is protective against accidental ingestion. Particularly, daily peanut oral immunotherapy induces increases in the amount of peanut required to induce a reaction. Previous research has also shown that some study participants can discontinue treatment and maintain the increased reaction threshold for short periods of time (4–8 weeks). One trial in young children done without a treated control group and another done in a real-world setting showed an ability to maintain the protection and to introduce peanut into the diet after treatment was discontinued. The beneficial protective clinical changes noted in these studies were associated with immune modulation, but they were also associated with adverse events in many participants.

Added value of this study

To our knowledge, this study is the first randomised, controlled, long-term blinded study of peanut oral immunotherapy in children younger than 4 years done in a multicentre (five US academic centres) trial design. The study provides long-term clinical efficacy, safety, and novel immunological data, along with predictors of response, among young children. These findings could inform clinicians about the potential benefits and risks of peanut oral immunotherapy for these patients.
this study, children underwent a 134-week blinded oral immunotherapy treatment period followed by a 26-week period without allergen exposure. We used oral food challenges to assess desensitisation after the 134-week treatment period and to assess remission after the 26-week no-exposure period, the longest period without allergen exposure studied to date.

Methods

Study design and participants

This multicentre, randomised, double-blind, placebo-controlled study was done at five academic medical centres in the USA by the Immune Tolerance Network. Institutional Review Boards at each site approved the protocol, which can be found online. Full description of all methods can be found in the appendix (pp 2–12). Throughout this study, peanut ingestion is defined in mg of peanut protein.

Children aged 12 months or older and younger than 48 months were screened for inclusion in the study. Inclusion criteria included the following: a clinical history of peanut allergy or avoidance without ever having eaten peanut, peanut-specific IgE levels of 5 kU/L or higher, a skin prick test (SPT) wheal size greater than that of saline control by 3 mm or more, and a positive reaction to a cumulative dose of 500 mg or less of peanut in a double-blind, placebo-controlled food challenge (DBPCFC). Key exclusion criteria included a history of severe anaphylaxis with hypotension to peanut, more than mild asthma or uncontrolled asthma, uncontrolled atopic dermatitis, and eosinophilic gastrointestinal disease (the full list of exclusion criteria is presented in the appendix p 2). Participants were recruited through referral clinics, multimedia advertisements, and social media. Written informed consent was obtained from the parents or guardians of the participating children.

Randomisation and masking

We used a computerised system to randomly assign participants (2:1) to peanut oral immunotherapy or placebo. A prespecified randomisation list was generated by a statistician with no other responsibilities during the trial. The study was masked to participants and study staff until all participants completed the end-of-study visits and the database was locked. An unmasked site investigational pharmacist received the randomisation code from the electronic data system for each participant and assigned study product to participants. All participants and study team members (except the investigational pharmacists) were masked to treatment group assignment. The order of peanut and placebo administration during DBPCFC was randomly assigned by an unmasked site dietitian, who also prepared the food challenge. All other study team members were masked to the challenge order. Investigational products were masked by a similar look, texture, and taste of oat flour and peanut when mixed with the vehicle (eg, applesauce or pudding), and the same volume of peanut or oat flour was provided for each product at each dosing level. No cases of accidental unmasking occurred.

Procedures

Participants were screened with standardised procedures for SPT, DBPCFCs, and immune assays, as defined in the protocol (appendix pp 3–10). Eligible participants were randomly assigned to receive peanut oral immunotherapy or placebo for daily oral dosing. We used lightly roasted, partly defatted (12% fat) peanut flour (Golden Peanut Company, Blakely, GA, USA) and oat flour placebo (Arrowhead Mills, Melville, NY, USA) for oral immunotherapy, manufactured at the University of North Carolina Good Manufacturing Practice facility under quality-controlled protocols.22 The oral immunotherapy protocol consisted of four phases: first, an initial dose escalation (0·1 mg to 6·0 mg); second, a build-up every 2 weeks to a maximal target dose of 2000 mg peanut daily (week 0 to about week 30), with a minimum dose of 250 mg reached after three attempts of build-up required to continue to daily maintenance; third, daily maintenance (weeks 30–134); and fourth, oral immunotherapy discontinuation (weeks 134–160). Dosing was modified, per protocol, for dose-related symptoms and illness. Adherence with the study product dosing was monitored by daily diaries and drug accountability logs. During all phases of the trial, participants were instructed to avoid dietary peanut consumption.

DBPCFCs were done up to a cumulative dose of 500 mg of peanut at study entry and up to a cumulative dose of 5000 mg of peanut at the end of dosing (week 134) and avoidance (week 160). Per protocol, participants progressed to week 160, independent of the DBPCFC outcome at week 134. Participants who passed the DBPCFC at week 134 were categorised as desensitised, and those who passed the DBPCFC at week 160 were categorised as being in remission (defined in the protocol as tolerant but revised to remission for clarity in this manuscript). For those passing the week 160 DBPCFC, an 8000 mg open-label feeding of peanut butter was conducted to confirm tolerability.

Immune assessments were done at baseline and throughout the study (weeks 30, 82, 134, and 160). SPT was done with peanut extract, saline, and histamine (Greer Laboratories, Lenoir, NC, USA). We tested basophil activation by flow cytometry on whole blood with and without stimulation with peanut extract.23 We measured total IgE and peanut-specific IgE and IgG4 in serum, and we measured peanut component-specific (Ara h1, h2, h3, and h6) IgE and IgG4 levels in plasma at baseline and longitudinally.

Outcomes

The primary endpoint was the proportion of participants desensitised after 134 weeks of oral immunotherapy,
defined as passing the 5000 mg peanut DBPCFC. Secondary endpoints included the proportion of participants who met remission, defined as passing the 5000 mg DBPCFC 26 weeks after oral immunotherapy discontinuation; the change in proportion of participants who passed the 5000 mg DBPCFC at weeks 134 and 160; the highest cumulative tolerated dose of peanut during DBPCFC; safety outcomes including incidence of all adverse events; rates of withdrawal from peanut oral immunotherapy or placebo; and changes in immune mechanistic markers.

The safety assessment and adverse events, including dosing reactions within 2 h of oral immunotherapy or DBPCFC dosing, were captured and entered in the electronic database. Oral immunotherapy dosing reactions were scored as mild, moderate, or severe. DBPCFC-related reactions were scored with a customised allergic reaction severity grading system. Although symptoms associated with anaphylaxis and systemic allergic reactions were recorded, the terms anaphylaxis and systemic allergic reactions were not defined as specified variables for this study. Dosing and challenge reactions were expected, and thus they were not reported as adverse events unless they resulted in hypotension, cyanosis, oxygen saturation lower than 92%, confusion, collapse, loss of consciousness, incontinence, or required more than two epinephrine doses; occurred more than 2 h after oral immunotherapy or DBPCFC dosing; or were not expected according to the investigational plan. Adverse events related to study procedures other than oral immunotherapy or DBPCFC or not associated with study procedures were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 4.03) and classified according to the Medical Dictionary for Regulatory Activities (version 16.0).

We used a gastrointestinal assessment questionnaire to qualitatively capture changes in symptoms (difficulty swallowing, refusal to eat, abdominal pain, or vomiting) at each study visit. If gastrointestinal symptoms were reported (appendix pp 8–9), we used a gastrointestinal questionnaire, modified for application in young children but not validated, in an attempt to further capture symptoms suggestive of eosinophilic oesophagitis. These assessments were used by investigators to determine the need for further investigation and management of gastrointestinal symptoms.

**Statistical analysis**

Desensitisation was imputed as a failure for participants who did not complete the DBPCFC at week 134 (with the tolerated dose defined as 0 mg), while remission was imputed as a failure for participants who did not complete the DBPCFC at week 160 (with the tolerated dose defined as 0 mg). The per-protocol sample for desensitisation and remission was defined as all intention-to-treat (ITT) participants who adhered to maintenance dosing and avoidance per protocol and had an evaluable DBPCFC at weeks 134 and 160 (ITT and per-protocol sample definitions are available in the statistical analysis plan. All assessments were done in the ITT population unless stated otherwise.

We calculated the sample size on the basis of a two-sample Pearson χ² test of proportions at a two-sided 0·05 level of significance, assuming a 15% dropout rate, 90% desensitisation in the peanut oral immunotherapy group, and 15% desensitisation in the placebo group. To provide 80% power for the remission endpoint but with an assumed remission rate of 40% in the peanut oral immunotherapy group and 15% in the placebo group, this required a sample size of 96 in the peanut oral immunotherapy group and 48 in the placebo group. This sample size provides greater than 99% power for the primary endpoint.
We compared categorical variables using the χ² test and continuous variables using the Kruskal-Wallis test. We used χ² and multivariable logistic regression analyses in the primary analysis of desensitisation and remission (appendix pp 11–12). Additionally, we did post-hoc analyses to identify predictors of desensitisation and remission in participants treated with peanut oral immunotherapy (appendix pp 11–12), with additional analyses done by categorising participants in three age categories: 12–23·9 months, 24–35·9 months, and 36–47·8 months. We did analyses of mechanistic data in the per-protocol sample. Analyses were done with SAS, version 9.4, and R, version 3.2.4. The statistical analysis plan and datasets are available through TrialShare.

The study was done under an FDA investigational new drug application and monitored by a National Institutes of Health (NIH)—National Institute of Allergy and Infectious Diseases (NIAID) Data and Safety Monitoring Board. The trial is registered on ClinicalTrials.gov, NCT03345160.

Role of the funding source
The funder of the study was involved with study design, data collection, data analysis, data interpretation, and writing of the manuscript.

Results
Between Aug 13, 2013, and Oct 1, 2015, 209 participants were enrolled in the study. Of these, 146 were randomly assigned to peanut oral immunotherapy (96 participants) or placebo (50 participants; figure 1). Participants had a median age of 39·3 months (IQR 30·8–44·7), were predominantly White (95 [65%] of 146), and 99 (68%) were boys and 47 (32%) were girls (table 1). Post-hoc analyses grouped participants by age at screening in three groups: 12·0–23·9 months (17 [12%] participants), 24·0–35·9 months (40 [27%] participants), and 36·0–47·9 months (89 [61%] participants; table 1). History of peanut allergy symptoms was reported in 91 (62%) participants, whereas 55 (38%) reported no exposure to peanut; differences were noted between these groups in median cumulative tolerated dose at baseline DBPCFC of 25 mg for those with allergy history versus 75 mg for those with no peanut exposure (p<0·0001). Overall, two (1%) participants had a reported history of peanut-associated anaphylaxis, but because neither of the two children had a history of severe anaphylaxis, both were included. Of participants randomly assigned, 70 (73%) of 96 who received peanut oral immunotherapy and 23 (46%) of 50 who received placebo completed the week 160 assessment, representing the per-protocol sample. Among participants who did not complete the trial, 15 (58%) of 26 who received peanut oral immunotherapy and 11 (42%) of 27 who received placebo discontinued before the week 134 DBPCFC, and 11 (42%) who received peanut oral immunotherapy and 12 (44%) who received placebo discontinued during avoidance (weeks 134–160; figure 1, appendix pp 17–19). Adjusting for treatment group, we compared baseline characteristics in ITT participants who discontinued before completing the week 160 DBPCFC.
of 146) with those of ITT participants who completed the week 160 DBPCFC (93 [64%]). The percentage of participants who discontinued differed across sites (36% in Arkansas, 49% in Johns Hopkins University, 41% in Mount Sinai, 6% in Stanford, and 50% in the University of North Carolina; p=0·015), and race (three [17%] of 18 were Asian, two [33%] of six were Black, six [22%] of 27 were mixed race, and 42 [44%] of 95 were White; p=0·039), and participants who discontinued before completing the week 160 DBPCFC had a higher SPT to peanut at screening (17·0 mm, SD 6·1) than that of participants who completed the week 160 DBPCFC (14·5 mm, SD 5·3; p=0·012).

Adherence to oral immunotherapy was high (appendix p 20). The median percentage of doses missed was 1·9% (IQR 0·9–3·8) for peanut oral immunotherapy and 2·0% (0·9–3·6) for placebo during build-up and 2·7% (1·1–4·4) for peanut oral immunotherapy and 1·4% (0·6–3·3) for placebo during maintenance. Among participants who completed the initial dose escalation, the number who missed three or more consecutive doses (predominantly due to concurrent illness) was nine (10%) of 94 for peanut oral immunotherapy and four (8%) of 50 for placebo during build-up and 20 (22%) of 90 for peanut oral immunotherapy and five (11%) of 44 for placebo during maintenance. Using the per-protocol sample, 59 (73%) of 81 participants with peanut oral immunotherapy and 28 (80%) of 35 with placebo reached the 2000 mg maintenance dose; the median highest dose received between week 30 and week 134 was 2000 mg (IQR 2000–2000) in both groups.

Assessment of desensitisation at week 134 showed that 68 (71%, 95% CI 61–80) of 96 participants who received peanut oral immunotherapy passed the 5000 mg DBPCFC compared with one (2%, 0·05–11) of 50 who received placebo (risk difference [RD] 69%, 95% CI 59–79; p<0·0001; figure 2A). Similar estimates were found after adjustment for site and age and baseline peanut-specific IgE (appendix pp 11–12). Compared with participants receiving peanut oral immunotherapy, a higher percentage of those receiving placebo dropped out of the study before the week 134 DBPCFC and were imputed as failures (figure 1), potentially artificially altering the relative desensitisation rates. However, we still detected a significant difference in desensitisation rates.

Figure 2: Primary and secondary outcomes
(A) Data are shown for the primary endpoint (desensitisation) at week 134 and secondary endpoint (remission) at week 160, measured by DBPCFC for the ITT sample and per-protocol sample, comparing peanut oral immunotherapy and placebo groups. (B) Data are shown for the peanut oral immunotherapy group; area under the curve=0·8072. (C) A contour plot of predicted probability of remission from the logistic regression model plotted against baseline peanut-specific IgE and age at screening; values in blue show probability of remission higher than 50%, whereas values in red show probability of remission lower than 50%. DBPCFC=double-blind, placebo-controlled food challenge. ITT=intention-to-treat. OIT=oral immunotherapy.
between the two groups when considering only participants in each group who completed the DBPCFC at week 134. In the per-protocol sample, 68 (84%, 95% CI 74–91) of 81 participants receiving peanut oral immunotherapy passed the 5000 mg DBPCFC compared with one (3%, 0.05–15) of 35 receiving placebo (p=0.0001). The median cumulative tolerated dose during the week 134 DBPCFC was 5005 mg (IQR 3755–5005) for peanut oral immunotherapy versus 5 mg (0–105) for placebo (p=0.0001); in the per-protocol sample, these values were 5005 mg (IQR 5005–5005) for peanut oral immunotherapy and 55 mg (5–255) for placebo (p=0.0001).

At the week 160 remission assessment (26 weeks after treatment discontinuation and peanut avoidance), 20 (21%, 95% CI 13–30) of 96 participants receiving peanut oral immunotherapy passed the 5000 mg DBPCFC compared with one (2%, 0.05–11) of 30 receiving placebo (RD 19%, 95% CI 10–28; p=0.0021; figure 2A). Similar estimates were found after adjustment for site, age, and baseline peanut-specific IgE (appendix pp 11–12). Again, compared with participants receiving peanut oral immunotherapy, a higher percentage of those treated with placebo dropped out of the study before the week 160 DBPCFC (figure 1). We detected a significant difference in remission between the two groups in the per-protocol sample: 20 (29%, 95% CI 18–41) of 70 participants receiving peanut oral immunotherapy versus one (4%, 0.11–22) of 23 receiving placebo were considered in remission (p=0.016). The median cumulative tolerated dose during the week 160 DBPCFC was 755 mg (IQR 0–2755) for peanut oral immunotherapy (appendix p 13) and 0 mg (0–55) for placebo (p=0.0001) in the ITT sample, and 1755 mg (755–5005) for peanut oral immunotherapy and 55 mg (5–255) for placebo in the per-protocol sample (p=0.0001). In the per-protocol sample, 40 (57%) of 70 participants receiving peanut oral immunotherapy compared with two (9%) of 23 receiving placebo could safely consume at least 1755 mg of peanut (appendix p 22). A significant proportion of participants receiving peanut oral immunotherapy who passed the 5000 mg DBPCFC at week 134 could no longer tolerate 5000 mg at week 160 (p<0.001). The participant receiving placebo who was desensitised at week 134 also achieved remission at week 160. During the 8000 mg open-label feeding, 17 (85%) of 20 participants receiving peanut oral immunotherapy and one (100%) of one receiving placebo passed, one receiving peanut oral immunotherapy failed the open feeding, and two participants also receiving peanut oral immunotherapy had undetermined status because the full dose was not eaten, although no symptoms were reported.

We measured immune parameters longitudinally and compared them between treatment groups (appendix pp 14–15) and peanut oral immunotherapy outcome groups (figure 3). Compared with placebo, peanut oral immunotherapy significantly decreased peanut-specific IgE, peanut component-specific IgE, peanut-specific IgE to total IgE ratio, and skin and basophil reactivity to peanut while increasing peanut-specific IgG4 and peanut component-specific IgG4 (appendix pp 14–15). In the peanut oral immunotherapy group, we observed reductions in peanut-specific IgE and SPT from baseline to week 30 (both p<0.0001). When comparing immune parameters in participants receiving peanut oral immunotherapy by treatment outcome (desensitisation and remission vs desensitisation and no remission vs no desensitisation and no remission), baseline differences demarcated the different outcome groups and these differences persisted throughout the study. Specifically, the desensitisation and remission group had the lowest baseline levels of peanut-specific IgE and Ara h2-specific IgE and the highest peanut-specific IgG4 to IgE ratio (figure 3). Compared with the peanut oral immunotherapy group, we observed significant increases in peanut-specific IgE, SPT, and basophil activation (figure 3, appendix p 14), as well as increases in peanut component-specific IgE (appendix p 15), as early as week 30 in the placebo group.

We assessed baseline predictors of desensitisation and remission using a predefined, multivariable logistic regression analysis applied to participants receiving peanut oral immunotherapy (appendix pp 11–12). On the basis of this analysis, a lower peanut component-specific IgE to Ara h6 ratio predicted desensitisation (odds ratio 0.35 per 10-fold increase, 95% CI 0.12–0.99; p=0.048) whereas a lower baseline peanut-specific IgE (0.12 per ten-fold increase, 0.03–0.46; p=0.0017) and younger age at screening (0.93 per month increase, 0.88–0.99; p=0.022) predicted remission (figure 2B). The effects of age at screening and baseline peanut-specific IgE on predicting the likelihood of remission within this study population are shown in figure 2C. Although the overall rate of remission in participants receiving peanut oral immunotherapy was 21% in the ITT sample and 29% in the per-protocol sample, remission was highly enriched in younger participants with low baseline peanut-specific IgE. In those receiving peanut oral immunotherapy, five (71%) of seven aged 12.0–23.9 months, seven (35%) of 20 aged 24.0–35.9 months, and eight (19%) of 43 aged 36.0–47.9 months attained remission (p=0.013, appendix p 23). The single participant receiving placebo to develop remission was one of three aged 12.0–23.9 months.

We assessed safety and adverse events throughout the 160-week masked study period. Dosing reactions during oral immunotherapy (table 2) occurred in all study phases, with 94 (98%) of 96 participants receiving peanut oral immunotherapy and 40 (80%) of 50 receiving placebo having at least one dosing reaction. The most frequently reported dose-related symptoms were skin, gastrointestinal, and respiratory disorders (table 2). Most reactions were mild or moderate and occurred more frequently with peanut oral immunotherapy (93 [97%] of 96 mild and 40 [42%] of 96 moderate) than
Articles

Placebo

Not desensitised and no remission

Desensitised and no remission

366

Articles

desensitised and remission versus both desensitised and no remission, and not desensitised and no remission.

DBPCFC=double-blind, placebo-controlled food challenge. *p<0·05 and †p<0·01 change from pre-treatment in the placebo group. ‡p<0·05 and §p<0·01 for

h2 (C) for the peanut oral immunotherapy outcome groups and placebo. The number of participants per group is the following: 23 in placebo, ten in not desensitised

and no remission, 40 in desensitised and no remission (39 in C), and 19 in desensitised or remission (18 in C). Data are shown as means with 95% CIs.

immunotherapy were categorised as desensitised or remission, desensitised and no remission, and not desensitised and no remission on the basis of the results of the

week 134 and week 160 DBPCFC. The panels show levels of peanut-specific IgE (A), peanut-specific IgG4 to IgE ratios (B), and IgE to peanut component-specific Ara

epinephrine administrations during maintenance

two were documented to resolve after oral immunotherapy discontinuation while one had persistent eosinophilic oesophagitis due to persistent symptoms;

participants receiving peanut oral immunotherapy during 35 events, including one (3%) in-clinic build-up event and 34 (97%) home-dosing events. 11 (32%) of 34 home-dosing events occurred during build-up in six (29%) of 21 participants, and 23 (68%) home-dosing events occurred during maintenance in 17 (81%) participants (table 3, appendix pp 16, 25). Grade 1 (mild) symptoms were reported in one (3%) of 35 epinephrine administrations, grade 2 (moderate) symptoms in 31 (89%) administrations, and grade 3 (severe) symptoms in three (9%) administrations. Two epinephrine doses were administered to two participants during 1600 mg maintenance dosing for symptoms of laryngeal oedema (stridor, hoarseness, or dysphagia), cough, and wheezing. One of these two participants had a previous grade 3 reaction at 25 mg requiring one epinephrine dose. Among participants receiving peanut oral immunotherapy, we observed a higher proportion of at-home epinephrine administrations during maintenance compared with build-up dosing, as well as more epinephrine administrations with oral immunotherapy doses higher than 600 mg. Seven of 21 participants receiving peanut oral immunotherapy requiring epinephrine administration withdrew from the study.

Among those receiving peanut oral immunotherapy who had at least one dose-related epinephrine administration, we observed site-specific differences in the frequency of administration (nine [41%] of 22 at Mount Sinai, four [40%] of ten at Arkansas, four [24%] of 17 at Stanford, two [11%] of 19 at University of North Carolina, and two [7%] of 28 at Johns Hopkins; p=0·022). In the ITT sample, we detected no significant effect of age at screening on at least one administration of epinephrine related to oral immunotherapy or any significant associations between at least one administration of epinephrine related to oral immunotherapy or any significant associations between at least one administration of epinephrine related to oral immunotherapy dosing and desensitisation or remission among participants receiving peanut oral immunotherapy. Epinephrine administration occurred during DBPCFC with a similar distribution between treatment groups, except for higher epinephrine use in the placebo group during the week 134 DBPCFC (appendix p 26). Symptoms occurring with oral immunotherapy or DBPCFC dosing and meeting adverse event criteria are presented in the appendix (pp 27–28). Serious adverse events occurred in nine participants; only one was study related during week 134 DBPCFC in a participant receiving placebo (appendix p 29). Three (3%) of 96 participants receiving peanut oral immunotherapy were referred for evaluation and endoscopy for eosinophilic oesophagitis due to persistent symptoms; two were documented to resolve after oral immunotherapy discontinuation while one had persistent disease.

Figure 3: Immunological changes over the course of the study

Data are shown for the sample of per-protocol participants who were evaluable while on treatment, during the avoidance phase, and by DBPCFC after avoidance.

Data are shown for timepoints including before treatment, week 30, week 82 or 95, week 134, and week 160 of the study. Participants receiving peanut oral

immunotherapy were categorised as desensitised or remission, desensitised and no remission, and not desensitised and no remission on the basis of the results of the

week 134 and week 160 DBPCFC. The panels show levels of peanut-specific IgE (A), peanut-specific IgG4 to IgE ratios (B), and IgE to peanut component-specific Ara

Figure 3: Immunological changes over the course of the study
Discussion

To our knowledge, this study is the first to evaluate efficacy and safety of peanut oral immunotherapy in children younger than 48 months with peanut allergy, with novel trial design features including a 134-week masked study period and a 26-week duration of...
Table 3: Summary of epinephrine administration

<table>
<thead>
<tr>
<th>Peanut OIT</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>Participants</td>
</tr>
<tr>
<td>At least one epinephrine dose given*</td>
<td>109</td>
</tr>
<tr>
<td>Associated with study product dosing†</td>
<td>35 (32%)</td>
</tr>
<tr>
<td>In-clinic dosing‡</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Dosing during initial dose escalation§</td>
<td>0</td>
</tr>
<tr>
<td>Dosing during build-up¶</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>Out-of-clinic dosing††</td>
<td>34 (97%)</td>
</tr>
<tr>
<td>Dosing during build-up¶</td>
<td>11 (32%)</td>
</tr>
<tr>
<td>Dosing during maintenance¶</td>
<td>23 (68%)</td>
</tr>
<tr>
<td>Associated with a study procedure†</td>
<td>97 (89%)</td>
</tr>
<tr>
<td>Overall oral food challenge DBPCFC) **</td>
<td>62 (64%)</td>
</tr>
<tr>
<td>Screen (baseline 500 mg DBPCFC)**</td>
<td>36 (58%)</td>
</tr>
<tr>
<td>Desensitisation (week 134 5000 mg DBPCFC)**</td>
<td>4 (6%)</td>
</tr>
<tr>
<td>Tolerance (week 160 5000 mg DBPCFC)**</td>
<td>22 (35%)</td>
</tr>
<tr>
<td>Not associated with study product dosing or a study procedure†</td>
<td>12 (11%)</td>
</tr>
<tr>
<td>Accidental exposure to peanut†</td>
<td>4 (33%)</td>
</tr>
<tr>
<td>Other allergen exposure††</td>
<td>8 (67%)</td>
</tr>
</tbody>
</table>

Data are n (%). This table includes all participants in the intention-to-treat sample. Participants could be counted in more than one row if the participant had multiple types of event. DBPCFC=double-blind, placebo-controlled food challenge. OIT=oral immunotherapy. The denominators used to calculate percentages are the following: the number of participants randomly assigned (*), either the number of events or participants with at least one administration of epinephrine (†), either the number of events or participants with at least one administration of epinephrine associated with study product dosing (‡), either the number of events or participants with at least one administration of epinephrine associated with in-clinic dosing (§), either the number of events or participants with at least one administration of epinephrine associated with out-of-clinic dosing (¶), either the number of events or participants with at least one administration of epinephrine associated with a study procedure (†), either the number of events or participants with at least one administration of epinephrine associated with an oral food challenge DBPCFC (**), or either the number of events or participants with at least one administration of epinephrine not associated with study product dosing or a study procedure (††).

Peanut OIT Placebo

368-0-35.9 months, and 19% of those aged 36.0-47.9 months achieving remission.

Although findings from a natural history study done in children aged 4 years or older showed that about 20% might develop natural tolerance without treatment, most of the children in that study were not challenged at diagnosis and many who developed tolerance had a much lower peanut-specific IgE than participants included in the IMPACT trial. Our study enrolled children with a low peanut reaction threshold (median cumulative tolerated dose at study entry of 25 mg or about one-12th of a peanut). After treatment, 20 (29%) of 70 per-protocol participants receiving peanut oral immunotherapy defined as achieving remission were able to consume 5000 mg (about 16 peanuts) whereas an additional 20 participants of those defined as not achieving remission could safely consume 1755–3755 mg (about 6–12 peanuts, a child-size serving portion) 26 weeks after treatment discontinuation. Therefore, a total of 40 (57%) of 70 children could safely consume 1755–3755 mg peanuts, indicating a substantial increase in peanut tolerability in participants who received peanut oral immunotherapy compared with study entry tolerability of 25 mg. This increase in peanut tolerability was not seen in participants who received placebo (only 4% consumed 1755–3755 mg of peanut). Treatment-induced remission in participants who received peanut oral immunotherapy was predicted by lower pretreatment peanut-specific IgE and younger age. The remission data, when combined with the observation that increases in IgE and reactivity to peanut were observed as early as week 30 in the placebo group compared with the peanut oral immunotherapy group, suggest a window of opportunity for more successful interventions at an early age in the course of peanut allergy.

To date, the only peanut oral immunotherapy studies that have assessed treatment outcomes by DBPCFC after a long period of treatment cessation are the current IMPACT trial and the POISED study. The POISED Study, using a different trial design in a population with a median age of 11 years (IQR 8–15), showed that after 104 weeks of peanut oral immunotherapy, 20% of participants who received peanut oral immunotherapy compared with study entry had sustained unresponsiveness to a cumulative dose of 4000 mg peanut and 32% to 900 mg peanut, assessed by DBPCFC after a 26-week treatment discontinuation. In IMPACT’s age group, which is younger than that in POISED, 21% of participants who received peanut oral immunotherapy were able to consume 5000 mg peanut and 57% of those in the per-protocol sample consumed at least 1755 mg 26 weeks after treatment discontinuation. A post-hoc analysis in IMPACT suggested an inverse relationship between age and remission outcome, with 71% of remission cases noted in the youngest subgroup of those receiving peanut oral immunotherapy. It might be that the enhanced window for remission closes very early.
The 19% rate of remission in the oldest participants in the IMPACT trial, aged 36.0–47.9 months, is similar to the overall rate of sustained unresponsiveness in the POISED (20%). Although IMPACT did not stratify randomisation of treatment groups by age, these findings on age effects might help guide the ideal design for future studies, including recommendations for including children younger than 24 months and following peanut oral immunotherapy in older children or adults with continued exposure through regular or intermittent peanut dosing or dietary introduction.

In addition to meaningful efficacy findings, the IMPACT trial contributes important, long-term safety data about peanut oral immunotherapy in young children. As in the DEVIL trial, a 2019 real-world study of peanut oral immunotherapy in Canadian preschool children showed that two-thirds of them developed at least one allergic reaction during dosing, 4% received epinephrine, and 10% dropped from the study. The IMPACT trial studied a well defined, randomised, controlled young population during 160 weeks of masked treatment and assessment. Overall, 98% of participants who received peanut oral immunotherapy in IMPACT had at least one dose-related reaction during treatment but no dose-related serious adverse events. Most oral immunotherapy dosing reactions were mild to moderate in severity, occurred during at-home dosing, and were managed without epinephrine administration or study withdrawal. Epinephrine administration during oral immunotherapy dosing was more frequent during at-home maintenance than at-home build-up dosing and was associated with doses greater than 600 mg. Compared with the PALISADE trial, epinephrine was administered more for dose-related symptoms among participants receiving peanut oral immunotherapy in IMPACT (52 [14%] of 372 in PALISADE vs 21 [22%] of 92 in IMPACT), as well as during maintenance. Gastrointestinal symptoms were common and similar to those reported in previous peanut oral immunotherapy studies. Biopsy-confirmed eosinophilic oesophagitis was noted in 3% of participants who received peanut oral immunotherapy in IMPACT. Importantly, the Aceves assessment tool used in IMPACT to monitor for symptoms of eosinophilic oesophagitis was not validated and was modified for use in young children. This, in combination with the gastrointestinal assessment questionnaire used, might have led to underreporting of the incidence of eosinophilic oesophagitis-related symptoms and diagnoses. Clearly, development of age-appropriate, validated assessment tools will shed light on this issue for the future.

Outcome groups were clearly distinguishable at baseline for children treated with peanut oral immunotherapy. Of special interest was the steady rise in peanut-specific and peanut component-specific IgE over time in the placebo group, indicating increasing sensitisation in young children with untreated peanut allergy and a potential closing of an important therapeutic window. By contrast, peanut oral immunotherapy-induced immunomodulation was characterised by a decline in peanut-specific IgE occurring by the end of build-up at week 30, earlier in the treatment course compared with oral immunotherapy studies involving older children.

This study has important limitations. Although we included children aged 12 to younger than 48 months, only 12% of children randomly assigned were younger than 24 months. The small number of children younger than 24 months resulted in larger CIs for the probability of remission in this subgroup. There was a high dropout rate during the required 26-week avoidance period, with a substantial differential between treatment groups that might have affected the outcome. Additionally, 27% of participants who received peanut oral immunotherapy and 20% of those who received placebo did not reach the maximal maintenance dose of 2000 mg, a factor that could have affected study outcomes.

A key secondary outcome of the IMPACT trial, assessed by DBPCFC after 26 weeks of allergen avoidance, is best described by the term remission. Recently, several terms have been used to describe possible surrogates for tolerance; however, there are currently no biomarkers that separate sustained unresponsiveness from remission from tolerance. Although desensitisation is a goal that offers substantial relief to patients and their families, attaining true tolerance would eliminate the need for regular allergen exposure and the fear of severe reactions, making it the ultimate goal of treatment. Future studies should focus on longer term follow-up, and thus should consider new designs that optimise the preferred options of families and participants for allergen avoidance or continued allergen consumption. The IMPACT design of a 26-week period of peanut allergen avoidance after treatment was designed in 2013; at that time, this was felt to be the best way to determine if these young children were tolerant. However, after the food challenge, the IMPACT study did not attempt to re-introduce peanut into the diet or to follow up the participants after the challenge, thus the study was unable to assess whether permanent tolerance was reached. Additionally, our definition of remission for this study—the ability to consume 5000 mg peanut—does not acknowledge the positive treatment effect noted in a large subset of those not achieving remission, since the majority of children consumed at least 1755–3755 mg peanut after treatment discontinuation, a level that has clinical relevance for young children.

In summary, the IMPACT Trial shows that peanut oral immunotherapy resulted in desensitisation in most children and remission in a substantial proportion of children compared with placebo, and that remission was predicted by younger age and lower baseline peanut-specific IgE. Further exploration of peanut oral immunotherapy in young children is warranted, focusing...
on age-defined benefits and risks for a potential valuable therapeutic window of opportunity for early intervention to induce remission.

Contributors
SMJ, AWB, MP, MK, JL-P, SS, DL, RY, and JJ designed the study. SMJ, EHK, KCN, AN-W, RAW, HAS, AMS, SC, JW, RDP, SBS, and AWB did the study. JJ, KS, DCB, HC, and MLS analysed data. MK, DL, and TQ did the immune assays. SMJ, EHK, KCN, AN-W, RAW, HAS, AMS, SC, JW, RDP, SBS, MK, JS, DCB, HC, JL-P, RY, DL, TQ, DW, MLS, SS, MP, LMW, and AWB critically reviewed the manuscript. SMJ, EHK, KS, DCB, HC, DL, TQ, DW, MLS, SS, MP, LMW, and AWB wrote the manuscript. DCB and HC verified the study data. The corresponding author had full control of all content and all authors had final responsibility with the funder for the decision to submit for publication.

Declaration of interests
SMJ reports grants from NIH-NIAID, DBV Allergy Research & Education (FARE), Immune Therapeutic, DBV Technologies, Astellas, Sanofi, Regeneron, and Genentech; and personal fees from FARE, EMMES Corporation, and Immune Therapeutics. EHK reports personal fees from DBV Technologies, Aimmune Therapeutics, AllerGenis, Ukko, Vibrant America, Allakos, Kenova Health, and Duke Clinical Research Institute; and grants from FARE and the Wallace Research Foundation. KCN reports grants from NIAID, National Heart, Lung, and Blood Institute, National Institute of Environmental Health Sciences, and FARE; other fees from World Allergy Organization and Cour Pharma; other support from Before Brande, Alladapt, Latitude, IgGenix, Immune Tolerance Network (ITN), and NIH clinical research centres; and pending patent applications for inhibition of allergic reaction to peanut allergen using an IL-33 inhibitor (62/467,389), special oral formula for decreasing food allergy risk and treatment for food allergy (62/119,014), basophil activation based diagnostic allergy test (S03.392), granulocyte-based methods for detecting and monitoring immune system disorders (12/686,121), methods and assays for detecting and quantifying pure subpopulations of white blood cells in immune system disorders (12/610,940), mixed allergen compositions and methods for using the same (18/064,936), and microfluidic device and diagnostic methods for allergy testing based on detection of basophil activation (62/767,444). AN-W reports grants from NIH-NIAID, DBV Technologies, Astellas Pharma, and FARE; and grants and personal fees from Nestle and Nutricia. RAW reports grants from NIAID, Aimmune, Astellas, DBV Technologies, Genentech, Regeneron, and Sanofi; and personal fees from UpToDate. HAS receives funding to his institution for grants from NIH-NIAID; consulting fees from DBV Technologies, N- Fold Therapeutics, and Siolsa; and stock options from DBV Technologies and N- Fold Therapeutics. AMS reports grants from NIAID-ITN, FARE, Immune, DBV Technologies, Astellas, Sanofi, Regeneron, and Genentech; and personal fees from DBV Technologies. JW reports grants from NIH-NIAID, and personal fees from DBV Technologies, ALK Abello, Genentech, and UpToDate. SBS reports grants from NIAID, Regeneron, DBV Technologies, Aimmune, Novartis, and Sanofi; and personal fees from AstraZeneca. MK reports grants from NIH and Department of Defence. JJ reports grants from NIAID. KS reports grants from NIH-NIAID. DCM reports grants from NIH-NIAID. HC reports grants from NIH-NIAID. DL reports grants from NIH-NIAID. All other authors declare no competing interests.

Data sharing
The trial dataset will be available to appropriate academic parties on request from the corresponding author, in accordance with the data sharing policies of ITN, with input from the investigator group where applicable, subject to submission of a suitable study protocol and analysis plan, on publication of all initial trial results.

Acknowledgments
Research reported in this publication was supported by NIH-NIAID under Award Number U1MA109565 and UM2AI117870. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Other sources of support include the National Center for Research Resources supported Clinical Translational Science Awards and Clinical Research Centers TR003107 (University of Arkansas for Medical Sciences), TR001111 (University of North Carolina), TR003142 (Stanford University), TR000067 (Mount Sinai University), and TR000424 (Johns Hopkins University School of Medicine). We thank the nurses, dietitians, study coordinators, laboratory staff, and other research staff at each institution and the NIAID Division of Allergy, Immunology and Transplantation’s Statistical and Clinical Coordinating Center at Rho; without their participation, the study could not have been done. Finally, we thank the families and children who kindly participated in this study. We attest to the accuracy and completeness of the reported data and for the fidelity of the report, the posted protocol, and the ClinicalTrials.gov posting. The study was designed by the investigators of ITN, with Stacie M Jones and A Wesley Burks as study chairs. The data were gathered by the investigators and analysed by biostatisticians at Rho. The manuscript was written collaboratively by Jones and Burks and reviewed and edited by the authors. The decision and approval to publish was made by the authors, as investigators in ITN, Rho, and the NIAID leadership.

References